The use of direct oral anticoagulants after pulmonary embolism regarding the bleeding risk in the countries without reimbursement Results from the Regional Pulmonary Embolism Registry
Background: Direct oral anticoagulants (DOACs) have become the standard of care for the treatment of pulmonary embolism (PE), but optimal drug selection requires individualized assessment, particularly in health systems without reimbursement policies.
Authors
- Sandra Pekovic
- B Božović
- Irena Mitevska (ORCID: https://orcid.org/0000-0002-2774-8559)
- D Tasić (ORCID: https://orcid.org/0000-0001-5957-9617)
- Bojan Mitrović
- Marija Benić
- Vladimir Miloradović (ORCID: https://orcid.org/0000-0001-5813-6769)
- Sonja Šalinger-Martinović (ORCID: https://orcid.org/0000-0001-9657-1665)
- Slobodan Obradović
- Boris Džudović (ORCID: https://orcid.org/0000-0001-9665-6052)
- Aleksandar Nešković (ORCID: https://orcid.org/0000-0001-8617-966X)
- Tamara Preradović Kovačević
- Jeftić
Institutions
- University of Banja Luka (BA)
- University of Belgrade (RS)
- University Clinic of Traumatology (AT)
- Klinički Centar Crne Gore (ME)
- Klinički centar Niš (RS)
- Military Medical Academy (BG)
- Institute for Pulmonary Diseases of Vojvodina (RS)
- Clinical Centre of Kragujevac (RS)
Publication Details
- Published
- 2025-09-28
- DOI
- https://doi.org/10.22541/au.175906449.97413669/v1
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00